Browsing by Author Pavlidis, N.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 116 to 135 of 317 < previous   next >
TitleAuthor(s)Issue date???itemlist.???
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant settingBriasoulis, E.; Andreopoulou, E.; Tolis, C. F.; Bairaktari, E.; Katsaraki, A.; Dimopoulos, M. A.; Fountzilas, G.; Seferiadis, C.; Pavlidis, N.24-Nov-2015-
Gastrointestinal, urologic and lung malignancies during pregnancyPentheroudakis, G.; Pavlidis, N.24-Nov-2015-
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology GroupNicolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, D.; Kalofonos, C.; Fountzilas, G.; Razi, E.; Kosmidis, P.; Pavlidis, N.24-Nov-2015-
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studySkarlos, D. V.; Kalofonos, H. P.; Fountzilas, G.; Dimopoulos, M. A.; Pavlidis, N.; Razis, E.; Economopoulos, T.; Pectasides, D.; Gogas, H.; Kosmidis, P.; Bafaloukos, D.; Klouvas, G.; Kyratzis, G.; Aravantinos, G.24-Nov-2015-
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trialPentheroudakis, G.; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, D.; Skarlos, D.; Hennig, G.; Samantas, E.; Bafaloukos, D.; Papakostas, P.; Kalofonos, H. P.; Pavlidis, N.; Fountzilas, G.24-Nov-2015-
Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?Dova, L.; Pentheroudakis, G.; Georgiou, I.; Malamou-Mitsi, V.; Vartholomatos, G.; Fountzilas, G.; Kolaitis, N.; Kitsiou, E.; Pavlidis, N.24-Nov-2015-
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development groupBriasoulis, E.; Pavlidis, N.; Terret, C.; Bauer, J.; Fiedler, W.; Schoffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P.24-Nov-2015-
Heterogeneity in cancer guidelines: should we eradicate or tolerate?Pentheroudakis, G.; Stahel, R.; Hansen, H.; Pavlidis, N.24-Nov-2015-
High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatmentPentheroudakis, G.; Goussia, A.; Voulgaris, E.; Nikolaidis, K.; Ioannidou, E.; Papoudou-Bai, A.; Grepi, K.; Kanavaros, P.; Pavlidis, N.; Bai, M.24-Nov-2015-
High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group studyFountzilas, G.; Skarlos, D.; Katsohis, C.; Pavlidis, N.; Giannakakis, T.; Bafaloukos, D.; Fahantidis, E.; Klouvas, G.; Beer, M.; Kosmidis, P.24-Nov-2015-
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancerAravantinos, G.; Dimopoulos, M. A.; Kosmidis, P.; Bafaloukos, D.; Papadimitriou, C.; Kiamouris, C.; Pavlidis, N.; Sikiotis, K.; Papakostas, P.; Skarlos, D. V.24-Nov-2015-
Immunization of patients with Sjogren's syndrome with pneumococcal polysaccharide vaccine: a randomized trialKarsh, J.; Pavlidis, N.; Schiffman, G.; Moutsopoulos, H. M.24-Nov-2015-
Immunohistochemical expression of DNA topoisomerase IIalpha in diffuse large B-cell lymphomasPapoudou-Bai, A.; Ioannidou, E.; Goussia, A.; Lambri, E.; Pentheroudakis, G.; Pavlidis, N.; Malamou-Mitsi, V.; Kanavaros, P.; Bai, M.24-Nov-2015-
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progressionIoachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D. L.; Agnantis, N. J.; Pavlidis, N.24-Nov-2015-
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinomaTsanou, E.; Ioachim, E.; Briasoulis, E.; Damala, K.; Charchanti, A.; Karavasilis, V.; Pavlidis, N.; Agnantis, N. J.24-Nov-2015-
Immunohistochemical Profiling of Signalling Pathways in Cancer of Unknown Primary (CUP)Pentheroudakis, G.; Petrakis, D.; Goussia, A.; Siozopoulou, V.; Bobos, M.; Fountzilas, G.; Cervantes, A.; Malamou-Mitsi, V.; Ciuleanu, T.; Pavlidis, N.24-Nov-2015-
Immunomodulation in colorectal cancer: disappointment or promise?Pentheroudakis, G.; Pavlidis, N.24-Nov-2015-
Inflammatory prostate cancer: an underestimated paraneoplastic clinical manifestationMauri, D.; Pentheroudakis, G.; Tolis, C.; Chojnacka, M.; Pavlidis, N.24-Nov-2015-
The influence of tamoxifen on serum triglyceridesElisaf, M. S.; Bairaktari, E.; Pavlidis, N.24-Nov-2015-
Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safetyLazaridis, G.; Pentheroudakis, G.; Pavlidis, N.24-Nov-2015-